Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Net operating loss carryforwards	$ 55,193	$ 52,393
Orphan Drug Credit	8,988	8,924
U.S. research and development credits	1,191	1,191
Stock-based compensation	748	803
Section 174 R&D costs	25
Amortization	1,041
Fixed assets	9	16
Accruals	31	84
Total deferred tax assets	67,226	63,411
Valuation allowance	$ (67,226)	$ (63,411)